SEC Filing Summary: BioSig Technologies, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on March 5, 2015, reporting events occurring on February 27, 2015. The filing details the consummation of a fifth closing under a Unit Purchase Agreement dated December 19, 2014, involving the sale of unregistered equity securities to accredited investors.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data relates to the capital raise transaction:
- Transaction Date: February 27, 2015
- Proceeds from Fifth Closing: $557,500
- Securities Issued (Fifth Closing): 5.575 units comprising 223,000 shares of Common Stock, "A" Warrants to purchase 223,000 shares (exercise price $2.50), and "B" Warrants to purchase 111,500 shares (exercise price $3.75).
- Cumulative Proceeds (All Closings): $2,983,100
- Cumulative Securities Issued: 29.831 units comprising 1,193,240 shares of Common Stock, "A" Warrants to purchase 1,193,240 shares, and "B" Warrants to purchase 596,120 shares.
Material Changes
The material change reported is the increase in outstanding equity and warrant obligations following the fifth closing. This transaction increased the total capital raised under the Purchase Agreement from $2,425,600 (after the fourth closing) to $2,983,100. The filing notes that the securities were sold in reliance on Section 4(a)(2) and Regulation D exemptions from registration.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the securities were unregistered. The text references a Registration Rights Agreement entered into by the investors but does not detail specific contingencies or unusual items affecting operations.
Investor Verification Checklist
- Verify the total number of outstanding shares and warrants post-transaction to assess dilution impact.
- Review the full text of the Unit Purchase Agreement and Registration Rights Agreement filed as exhibits to the 2014 Form 10-K for terms regarding exercise prices and vesting.
- Confirm the company's use of the $2,983,100 in aggregate proceeds raised under the agreement.
- Check subsequent filings for any further closings under the Purchase Agreement or changes in the company's capital structure.